drug · small molecule

PALSONIFY

updated 2mo ago

by $CRNX Crinetics Pharmaceuticals, Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Unknown (across all indications), with 3 investigational indications.

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

PALSONIFY

generic

PALTUSOTINE HYDROCHLORIDE

MOA

12.1 Mechanism of Action Similar to the natural hormone somatostatin, paltusotine suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Paltusotine exerts its pharmacological activity via selective agonism (>4000-fold) at somatostatin receptor 2 (SSTR2) and exhibits little or no affinity for other SST receptor subtypes. Paltusotine inhibited cyclic adenosine monophosphate accumulation via human SSTR2 activation with an average drug (agonist) concentration that results in half-maximal response (EC 50 ) of 0.25 nM.

indication

1 INDICATIONS AND USAGE PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option ( 1 ).

PALSONIFY

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside